In 2023 the rule was simple — hold your weekly shot for a week. In 2024 five medical societies replaced that with something more useful, and more demanding: most patients can keep taking it, if the care team knows exactly where you are in your regimen.
GLP-1 receptor agonists slow gastric emptying. That's part of how they work — food sits longer, you feel full sooner. Under general anesthesia or deep sedation, it becomes a different problem: food still in the stomach can be regurgitated and aspirated into the lungs, and aspiration pneumonia can be fatal.
The size of the delay is worth knowing, because it is smaller than the alarm around it suggests. A 2024 meta-analysis in the American Journal of Gastroenterology found solid-phase gastric emptying was delayed by roughly 36 minutes on average in people taking GLP-1 agonists. Liquid-phase emptying was barely affected. That is a real delay, not a catastrophic one — which is exactly why the guidance moved away from a blanket rule.
The American Society of Anesthesiologists issued consensus-based guidance in June 2023. It was a flat schedule, applied regardless of indication, dose, or procedure type.
Easy to follow — and that was the criticism. Holding a weekly shot means losing glycemic control in people with type 2 diabetes, restarting titration, and in practice often cancelling procedures over a risk that hadn't been individually assessed.
In October 2024 the ASA, the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and SAGES released joint guidance that replaced the schedule with a risk assessment. Its headline: most patients should continue their GLP-1 before elective surgery.
It also flagged something the earlier rule invited — withholding a GLP-1 purely because a patient has obesity, absent any listed risk factor, may constitute bias and should be avoided.
Four things move you into the higher-risk group: being in the dose-escalation phase, being on a higher or weekly dose, having active GI symptoms like nausea, vomiting or constipation, and having a condition that already slows emptying, such as gastroparesis or Parkinson disease. Without those, the guidance says you may continue. With them, the mitigations are a 24-hour liquid diet, gastric ultrasound before the procedure, or deferring until escalation is over.
Sources: Kindel et al., Surg Endosc 2025 — multisociety perioperative guidance · Joshi et al., ASA consensus-based guidance, 2023 (updated Nov 2024) · Hiramoto et al., Am J Gastroenterol 2024 — gastric emptying meta-analysis · Mishra et al., Cleve Clin J Med 2025. See the ASA announcement and the Cleveland Clinic summary.
Your exact last-dose date. "Sometime last week" isn't enough to place you on a 4-to-8-week escalation timeline. The date and the milligram strength are what the anesthesia team is actually assessing.
Whether you're still titrating. The escalation phase typically runs four to eight weeks, and it's the single risk factor most likely to get an elective procedure deferred. Knowing you finished ramping two months ago changes the conversation.
Your recent GI symptoms. Nausea, vomiting, bloating or constipation in the days before a procedure matter more than the drug itself.
Endoscopy follows slightly different logic — AGA guidance leans toward continuing GLP-1s prescribed for diabetes, and suggests a liquid diet the day before may be a safer trade than stopping the drug. Restart timing after any procedure is a prescriber decision; there's no established rule for it yet.
GLP1ShotDay keeps a dated log of every shot and dose, which is the exact record this conversation needs — and the same log you can hand over on the day.
This article summarizes published professional-society guidance and peer-reviewed research for general education. It is not medical advice. Do not start, stop, or hold a prescribed medication before a procedure without instruction from your anesthesia, surgical, and prescribing care teams.